{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "FBRX", "name": "Forte Biosciences, Inc.", "url": "https://frontierpicks.com/dossiers/FBRX/", "json_url": "https://frontierpicks.com/dossiers/FBRX.json", "status": "DORMANT", "current_conviction": "SUPREME", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Forte Biosciences’ $77-per-share cash-acquisition thesis was resolved by the 2026-08-27 merger completion. Official restoration of the former common equity would reopen the case; Nasdaq records 2026-08-26 as its last trading date.", "invalidation_trigger": "A daily close below $77.00 after 2026-08-27, authenticated by an official notice restoring trading in the former Forte common equity, would invalidate the terminal-listing thesis; the historical 2026-08-26 close does not qualify.", "catalyst_date": null, "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "precision-biotech-therapeutics", "m-and-a-special-situations" ], "tags": [], "sources": [], "notes": [ "FBRX common stock ceased trading on the Nasdaq Capital Market with the merger completion announced 2026-08-27; the symbol has no live listing.", "Shares not tendered were converted in the back-end merger into the right to receive the same $77.00 per share in cash via the paying agent.", "The two-step tender structure meant no shareholder vote; non-tendering holders may hold appraisal rights under Delaware law.", "FB102 clinical exposure now sits inside argenx; Forte no longer files standalone financial statements as a reporting company.", "Any residual over-the-counter quote for the symbol would not represent the terminated Nasdaq listing." ], "body_markdown": "## Current Thesis\n\nForte Biosciences’ cash-acquisition thesis was resolved by the merger completed on 2026-08-27; reopening it would require official restoration of the former common equity. Argenx announced completion at $77.00 per share, while Nasdaq identifies 2026-08-26 as the last trading date. The narrative is dead following that completed transaction, rather than awaiting another clinical or financing catalyst. [Completion announcement](https://www.sec.gov/Archives/edgar/data/1697862/000114036126034700/ef20081196_ex99-1.htm), [Nasdaq corporate-action notice](https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-597).\n\nThe dated development since the 2026-09-05 coverage is argenx’s 2026-09-17 announcement of shareholder-meeting results and director appointments. Its newsroom lists that event without announcing a reopening of the Forte transaction. That supports continuity of the completed-merger interpretation, not a renewed FBRX catalyst. [Argenx newsroom, reviewed 2026-09-19](https://argenx.com/newsroom).\n\n## Bull Case\n\n- **The acquisition reached completion.** Argenx’s 2026-08-27 announcement confirms the merger and acceptance of tendered shares for payment. Acceptance establishes the contractual outcome; it does not establish that every recipient had received cash that day. [Completion announcement](https://www.sec.gov/Archives/edgar/data/1697862/000114036126034700/ef20081196_ex99-1.htm).\n- **The tender percentage needs precision.** Forte’s 2026-08-27 Form 8-K reports 19,894,879 tendered shares; approximately 87.13% includes shares already owned by the parent. Comparing tendered shares alone with that percentage cannot establish warrant exercises or a changed denominator. [Forte closing filing](https://www.sec.gov/Archives/edgar/data/1419041/000114036126034698/ef20081182_8k.htm).\n\n## Bear Case\n\n- **The listed upside has ended.** Nasdaq records the merger before the 2026-08-27 market opening and suspension effective 2026-08-28. The former acquisition spread therefore supplies no continuing listed-price opportunity. [Nasdaq corporate-action notice](https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-597).\n- **Clinical development belongs to argenx.** The 2026-08-27 completion announcement places FB102 in argenx’s pipeline and describes celiac-disease data as expected in the second half of 2026. It supplies no exact readout date. Any inference that those results could reprice the former common equity would require its official restoration. [Completion announcement](https://www.sec.gov/Archives/edgar/data/1697862/000114036126034700/ef20081196_ex99-1.htm).\n\n## Setup & Price Structure\n\nThe supplied adjusted daily series ends at $76.99 on 2026-08-26, also its 52-week high, after a three-month price increase of 270.7%. These are historical measurements. Nasdaq independently identifies that session as the last trading date and records the subsequent halt and suspension. [Nasdaq corporate-action notice](https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-597).\n\nThe supplied news record clusters acquisition coverage on 2026-07-27, followed by Barclays’ 2026-07-28 downgrade to Equal-Weight and its $77 analyst price target. That is observable coverage concentration around the cash offer. It does not measure retail ownership, short exposure or expanding participation; those positioning figures are missing. No moving-average value was supplied.\n\n## Catalyst Calendar (next 30 days)\n\n2026-09-19–2026-10-19: No dated FBRX catalyst was identified in the reviewed announcements. Nasdaq’s completed suspension and argenx’s newsroom support treating the former listing as inactive. The elapsed merger date is not an upcoming event. [Nasdaq notice](https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-597), [Argenx newsroom, reviewed 2026-09-19](https://argenx.com/newsroom).\n\n## What Would Change Our Mind\n\nRestoration of the former common equity would break the terminal interpretation: a daily close below $77.00 after 2026-08-27 would qualify only if an official exchange or company notice authenticated resumed trading in that same equity. The supplied $76.99 close occurred on 2026-08-26 and cannot invalidate a subsequent completion finding. Nasdaq’s suspension notice makes the distinction necessary; an isolated stale quote would not establish restoration. [Nasdaq corporate-action notice](https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-597).\n\nThe resolved acquisition provides no remaining prospective price path to grade. Forte’s 2026-08-27 filing also preserves specified appraisal exceptions, so completion should not be described as proof that every residual legal claim disappeared. [Forte closing filing](https://www.sec.gov/Archives/edgar/data/1419041/000114036126034698/ef20081182_8k.htm).\n\n## Correlation Notes\n\nThe 2026-07-27 agreement fixed cash consideration at $77 per share rather than an exchange ratio tied to argenx stock. This supports a single-company acquisition interpretation of the closing period. No paired return series was supplied, so a numerical correlation with biotechnology shares or argenx cannot be stated. The historical theme tags describe the transaction and drug program, not evidence of a continuing group move. [Acquisition announcement](https://argenx.com/news/2026/press-release-3333257.html).", "first_seen": "2026-08-12", "last_analyzed": "2026-09-19T21:07:20+00:00", "last_synthesized": "2026-09-19", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }